Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and movement disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 26, 2022.

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

In a multiday ascending dose trial, pharmacokinetic analysis indicated a direct linear relationship between drug dosing concentration and blood plasma levels for each of the 5 days of dosing.

The publication’s findings were consistent with previous scientific literature suggestive that Alzheimer disease is a multifactorial disease, where several pathways interlink and cause cognitive impairments.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

More than 60% of patients with early-onset dementia with Lewy bodies had a least 3 of the 5 identified factors at first clinic visit, compared with fewer than 20% of those with early-onset Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]

The director of the Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed new research which looked at the differences in functional connectivity for men and women of older age.

The AAV1 gene therapy, PBFT02, is being assessed in a phase 1/2 trial called upliFT-D (NCT04747431), which is planned to take place over the course of 24 months in patients with frontotemporal dementia with granulin mutations.

Here's some of what is coming soon to NeurologyLive® this week.

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.

The field of Alzheimer disease has entered a new era of earlier detection, creating an opportunity to redefine treatment and the clinical care of patients.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 12, 2022.

The associate professor of neuropsychology at the University of Miami Miller School of Medicine provided insight on how persistent impairments seen on a cognitive screening tool may differentiate cognitive status. [WATCH TIME: 6 minutes]

The chair of the nephrology division at Mayo Clinic discussed the major questions surrounding preeclampsia and its long-term effects, as well as whether new findings change the way clinicians treat patients with the condition. [WATCH TIME: 4 minutes]

The assistant director of computational biology at Stanford University discussed where the Alzheimer disease community stands on gene therapies that target APOE, and whether missense variants will play a role. [WATCH TIME: 4 minutes]

The professor of psychiatry and cell biology at NYU Langone discussed how validation of lysosomal autophagy will only simplify the understanding of the root causes of Alzheimer disease. [WATCH TIME: 4 minutes]

The director of the Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic provided insight on data presented at AAIC 2022 that evaluated the interaction effect of sex and diagnosis on functional connectivity in various cognitive stages. [WATCH TIME: 3 minutes]